Tarextumab: Updated Phase Ib/II data

Updated data from 27 patients with SCLC in the dose-escalation Phase Ib portion of the international Phase Ib/II PINNACLE trial showed that IV 5-15 mg/kg tarextumab every 3 weeks plus etoposide and ci...